Jim joined Maverick as CEO in 2017. Prior to Maverick, Jim was an executive with Pacira Pharmaceuticals (Nasdaq: PCRX) during its 9 year hypergrowth period from a venture funded, 70 employee, development stage company into a $2B market cap, 500+ employee, commercial stage company selling EXPAREL® (bupivacaine), a growing $300M+ revenue product, jointly with J&J. As President of Pacira, Jim oversaw global R&D and manufacturing activities, as well as commercial and medical support activities. He joined Pacira as Chief Financial Officer in 2008, and led the company’s 2011 IPO and subsequent debt and equity financings until hiring his successor in 2016. Prior to Pacira, Jim was an executive with Bioenvision (NASDAQ: BIVN), a commercial stage oncology company acquired by Genzyme, and Merrimack Pharmaceuticals, an oncology-focused systems biology company. Earlier in his career he spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies.
Jim currently serves on the Board of Aquestive Therapeutics (NASDAQ: AQST) and Matinas BioPharma (NYSE: MTNB).
Jim received a Bachelor of Science in Physics from Wake Forest University and an MBA from the University of Michigan.